Real Hope For Lupus As AZ's Anifrolumab Impresses In Phase II
This article was originally published in Scrip
A Phase II trial of AstraZeneca's investigational monoclonal antibody, anifrolumab, in patients with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and secondary endpoints. The data were presented at the American College of Rheumatology 2015 Scientific Meeting in San Francisco this week.
You may also be interested in...
The second Phase III TULIP trial for AstraZeneca’s anifrolumab has succeeded where the first failed by hitting a new primary endpoint in systemic lupus erythematosus.
Another one of AstraZeneca’s more left-field product candidates, its investigational lupus therapy anifrolumab, has disappointed at Phase III.
French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.